This is a working overview of Cardarine, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-09 and is reviewed periodically as new material appears.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
=== Breastfeeding === ACE inhibitors may be used with caution during breastfeeding due to evidence showing small amounts being present in breastmilk. Enalapril is most commonly prescribed and has the most data published. The medications are considered safe for the mother.
=== Climate === The district's climate is moderate for Canada due to its southerly location within the country and its proximity to Lake Ontario. It has a humid continental climate (Köppen climate classification Dfb), with warm, humid summers and generally cold winters. Mean temperature and precipitation tends to be slightly lower than the downtown core or south Etobicoke for instance, due in part to the weather station being farther from the moderating influence of the lake and also because of its more northeast location. Conditions vary based on proximity to the lake, with fog more common in the south and areas close to the lake noticeably cooler on hot summer days.
April 9: Law establishing the postal savings bank: regardless of her marital status, a wife does not need her husband's permission to open a postal savings account or withdraw money from it—unless the husband expressly objects. June 16: Law establishing free primary education in public schools: these also include girls' schools in communes with more than 400 inhabitants. August 2: Decree organizing nursery schools—coeducational, they accept children aged 2 to 7; all directors and workers are women; female general and departmental inspectors are assigned to their oversight. Girls are granted access to secondary education, with specific provisions and a diploma different from the baccalaureate (which boys may obtain). March 28, 1882: Law on mandatory primary education for both boys and girls between the ages of 6 and 13; school curricula differ only in that girls learn needlework and boys take military exercises. July 27, 1884: Law reinstating divorce. 1885
A metatarsophalangeal joint sprain is an injury to the connective tissue between the foot and a toe (at a metatarsophalangeal joint, one of the joints in the ball of the foot). When the big toe is involved, it is known as "turf toe".
Sources: en.wikipedia.org
=== Education === Al-Fawzan enrolled in the public school in Ash-Shamasiyyah in 1950 (1369 AH). He completed his education at Al-Faysaliyyah School in Buraydah in 1952 (1371 AH), and was appointed as a primary school teacher. He then enrolled at the Ma'had Al-'Ilmī (The Institute of Knowledge) in Buraydah when it opened in 1954 (1373 AH), and graduated from it in 1958 (1377 AH). He joined the Kullīyat Ash-Sharīʿah (The College of Sharīʿah) in Riyadh and graduated in 1962 (1381 AH). Al-Fawzan later obtained a master’s degree in fiqh in the field of inheritance law, with a thesis titled: "Al-Taḥqīqāt Al-Marḍiyyah fī Al-Mabāḥith Al-Farḍiyyah" (A Satisfactory investigation into the issues of obligatory Shares in Inheritance). He subsequently obtained a doctorate in fiqh from the same college, with a dissertation titled: "Aḥkām Al-Aṭʿimah fī Al-Sharīʿah Al-Islāmiyyah" (The Rulings of Foods in the Islamic Sharīʿah).
In 1957, Marvin Margoshes and Bert L. Vallee at Harvard Medical School discovered that in horse kidney cortex, cadmium and zinc levels appeared to be maintained by binding to another molecule which they identified as a protein. They reported in the Journal of the American Chemical Society, concluding:The low sedimentation constant and high metal content of this material are indicative of a low molecular weight protein, probably containing a small number of cadmium atoms per molecule. Characterization of this unusual natural product is in progress.In 1958, Vallee presented the discovery at the International Congress of Biochemistry held in Vienna, and suggested that cadmium must be a natural biomolecule using the unknown protein. He pursued the research with his student Jeremias H. R. Kägi and was able to identify the new protein in 1960. The conclusion in The Journal of Biological Chemistry runs:The present study reports the isolation and characterization of a protein from equine renal cortex which contains 2.9% of cadmium, 0.6% of zinc, and 4.1% of sulfur per g dry weight of protein. This protein has been termed metallothionein in view of its metal and sulfur content.Vallee and Kägi reported further confirmation in the same journal in 1961. They later realised that metallothionein was not a single type of protein. With their collaborators, they could differentiate another related protein but with different amino acid properties and gave the name "metallothionein-1B" in 1970.
A Type III civilization should be detectable because of the large amount of radiation captured on a galaxy-wide scale. Calissendorff suggests using 75% of the total light emitted by a galaxy to determine that a Type III civilization uses many Dyson spheres. If only three or four of these spheres occupy the galaxy, it does not necessarily mean that the civilization has reached Type III, and it may still be in transition; however, such civilizations may remain beyond the reach of our understanding and instruments. Semay observes that "a Type III civilization should not be confused with what science fiction writers call a 'galactic empire'", knowing that it can only exist if interstellar travel is achieved. Semay argues that there is no evidence that this will ever be possible. Based on Dyson's calculations, Semay believes that such a journey would take three centuries, with an average distance between stars of about 7 light years. Overall, the speed of the colonization front, which ranges from 4×10−4 to 5×10−3 light-years/year, would result in humanity spreading throughout the galaxy in a period of 16 to 200 million. "A Type III civilization, having thus "domesticated" its galaxy by building a large number of Dyson spheres, would be detectable over intergalactic distances of several million light-years." A Type III civilization could theoretically live inside a supermassive black hole, in a stable periodic orbit, which would make it completely undetectable, according to V. I. Dokuchaev.
Sources: en.wikipedia.org
=== Plasmapheresis and IVIG === If the myasthenia is serious (myasthenic crisis), plasmapheresis can be used to remove the putative antibodies from the circulation. Also, intravenous immunoglobulins (IVIGs) can be used to bind the circulating antibodies. Both of these treatments have relatively short-lived benefits, typically measured in weeks, and often are associated with high costs, which make them prohibitive; they are generally reserved for when MG requires hospitalization.
The European Commission is the main executive body of the European Union. Article 17(1) of the Treaty on European Union states the commission should "promote the general interest of the Union" while Article 17(3) adds that Commissioners should be "completely independent" and not "take instructions from any Government". Under Article 17(2), "Union legislative acts may only be adopted on the basis of a Commission proposal, except where the Treaties provide otherwise". This means that the commission has a monopoly on initiating the legislative procedure, although the council or Parliament are the "de facto catalysts of many legislative initiatives".
The adventitia ( ad-ven-TI-shuh) is the outer layer of fibrous connective tissue surrounding an organ. The outer layer of connective tissue that surrounds an artery, or vein – the tunica externa, is also called the tunica adventitia. To some degree, its role is complementary to that of the serosa, which also provides a layer of tissue surrounding an organ. In the abdomen, whether an organ is covered in adventitia or serosa depends upon whether it is peritoneal or retroperitoneal:
Plasma as a blood product prepared from blood donations is used in blood transfusions, typically as fresh frozen plasma (FFP) or Plasma Frozen within 24 hours after phlebotomy (PF24). When donating whole blood or packed red blood cell (PRBC) transfusions, O- is the most desirable and is considered a "universal donor," since it has neither A nor B antigens and can be safely transfused to most recipients. Type AB+ is the "universal recipient" type for PRBC donations. However, for plasma the situation is somewhat reversed. Blood donation centers will sometimes collect only plasma from AB donors through apheresis, as their plasma does not contain the antibodies that may cross react with recipient antigens. As such, AB is often considered the "universal donor" for plasma. Special programs exist just to cater to the male AB plasma donor, because of concerns about transfusion related acute lung injury (TRALI) and female donors who may have higher leukocyte antibodies. However, some studies show an increased risk of TRALI despite increased leukocyte antibodies in women who have been pregnant.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.